Invesco
TSHA icon

Invesco’s Taysha Gene Therapies TSHA Stock Holding History

Invesco’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.8M Sell
264,379
-103,642
-28% -$613K ﹤0.01% 2634
2026
Q1 		$1.65M Sell
368,021
-964,759
-72% -$4.49M ﹤0.01% 2633
2025
Q4 		$7.33M Buy
1,332,780
+1,052,987
+376% +$5.11M ﹤0.01% 2043
2025
Q3 		$915K Buy
279,793
+76,122
+37% +$216K ﹤0.01% 2978
2025
Q2 		$470K Buy
203,671
+43,772
+27% +$95.1K ﹤0.01% 3182
2025
Q1 		$222K Buy
159,899
+72,544
+83% +$121K ﹤0.01% 3476
2024
Q4 		$151K Buy
87,355
+1,674
+2% +$3.47K ﹤0.01% 3564
2024
Q3 		$172K Sell
85,681
-312,069
-78% -$685K ﹤0.01% 3545
2024
Q2 		$891K Buy
+397,750
New +$1.16M ﹤0.01% 2991

Other funds holding TSHA

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco's TSHA Position: Q2 2026 in Review

Invesco reduced its Taysha Gene Therapies (TSHA) stake by 28% in Q2 2026, selling an estimated $613K and leaving 264,379 shares worth $1.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2634.

Invesco first reported a position in TSHA in Q2 2024 and has held it in 9 quarters since. The position peaked at $7.33M in Q4 2025. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Invesco held 264,379 shares of Taysha Gene Therapies worth $1.8M as of Q2 2026.
  • Invesco sold 103,642 Taysha Gene Therapies shares in Q2 2026, an estimated $613K.
  • Taysha Gene Therapies made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2634 holding.
  • Invesco first reported a position in Taysha Gene Therapies in Q2 2024 and has held it in 9 quarters since.
  • Invesco's Taysha Gene Therapies position peaked at $7.33M in Q4 2025.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.